These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 25818740

  • 1. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 3. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R, Kobayashi K, Usuki J, Yomota M, Nishitsuji M, Shimokawa T, Ando M, Hino M, Hagiwara K, Miyanaga A, Seike M, Kubota K, Gemma A, North East Japan Study group.
    Thorac Cancer; 2020 Jul 01; 11(7):1876-1884. PubMed ID: 32421226
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K, North East Japan Study Group.
    Lung Cancer; 2016 Sep 01; 99():131-6. PubMed ID: 27565928
    [Abstract] [Full Text] [Related]

  • 6. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
    Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.
    Lung Cancer; 2012 Sep 01; 77(3):567-71. PubMed ID: 22770372
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I.
    Clin Lung Cancer; 2014 May 01; 15(3):197-201. PubMed ID: 24492162
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S.
    Lung Cancer; 2014 Sep 01; 85(3):429-34. PubMed ID: 25047675
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.
    Br J Cancer; 2013 Aug 06; 109(3):552-8. PubMed ID: 23860535
    [Abstract] [Full Text] [Related]

  • 10. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H.
    Oncol Rep; 2013 Jun 06; 29(6):2332-40. PubMed ID: 23525453
    [Abstract] [Full Text] [Related]

  • 11. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 12. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug 01; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 13. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar 01; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

  • 14. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S.
    Clin Cancer Res; 2007 Oct 01; 13(19):5918-25. PubMed ID: 17908988
    [Abstract] [Full Text] [Related]

  • 15. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.
    Anticancer Res; 2014 Jan 01; 34(1):215-20. PubMed ID: 24403465
    [Abstract] [Full Text] [Related]

  • 16. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 01; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 17. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
    Christoph DC, Eberhardt WE.
    Curr Opin Oncol; 2014 Mar 01; 26(2):171-81. PubMed ID: 24441503
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 01; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 19. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.
    J Thorac Oncol; 2012 Sep 01; 7(9):1440-8. PubMed ID: 22895141
    [Abstract] [Full Text] [Related]

  • 20. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 01; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.